{"nctId":"NCT00182000","briefTitle":"Effectiveness of D-Cycloserine as an Aid to Enhance Learning for Individuals With OCD Receiving Behavior Therapy","startDateStruct":{"date":"2003-11"},"conditions":["Obsessive-Compulsive Disorder"],"count":33,"armGroups":[{"label":"Seromycin","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: seromycin","Behavioral: Behavior Therapy"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Behavioral: Behavior Therapy"]}],"interventions":[{"name":"seromycin","otherNames":["D-Cycloserine"]},{"name":"Behavior Therapy","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Structured Clinical Interview for DSM-IV (SCID) diagnosis of Obsessive Compulsive Disorder\n* Score of greater than 16 on the Yale-Brown Obsessive Compulsive Scale\n* Negative urinary beta-Human Chorionic Gonadotropin (hCG) test\n\nExclusion Criteria:\n\n* Currently taking or have taken an unstable dose of psychotropic medications within 2 months prior to enrollment\n* Currently taking medications that may interfere with the study medication\n* History of seizure disorder or other serious medical illnesses (e.g., cardiovascular, liver, kidney, respiratory, endocrine, neurologic, or blood-related disease)\n* Current diagnosis of tuberculosis\n* Other psychiatric diagnoses (e.g., alcohol dependence, bipolar disorder, psychosis, organic mental disorder, or development disorder) that are of greater concern than the obsessive-compulsive disorder diagnosis\n* Currently taking medications that may lower seizure threshold (e.g., including clozapine, pethidine, and the following antibiotics in high dosage: penicillins, cephalosporins, amphotericin, and imipenem)\n* Poses a serious suicidal or homicidal threat\n* Currently undergoing psychotherapy\n* Failure to benefit from ten or more sessions of previous Exposure and Response Prevention (ERP) treatment\n* Pregnant or breastfeeding","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Yale-Brown Obsessive Compulsive Scale (YBOCS)","description":"A clinician-rated measure of obsessive-compulsive disorder severity. Each item is scored on a 0 to 4 range. Total scores are obtained by summing items 1-10 and thus range from 0 to 40 with higher scores indicating greater symptom severity. Results posted below are from the post-treatment evaluation (after 10 treatment sessions).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.2","spread":"7.2"},{"groupId":"OG001","value":"14.5","spread":"6.4"}]}]}]},{"type":"SECONDARY","title":"Clinical Global Impressions Scale (CGI)","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Beck Depression Inventory (BDI)","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Beck Anxiety Inventory (BAI)","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Obsessional Beliefs Questionnaire (OBQ)","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Short-Form Health Survey (SF-36)","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Disability Inventory","description":null,"paramType":null,"dispersionType":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":14},"commonTop":[]}}}